Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
108 participants
OBSERVATIONAL
2004-10-14
2007-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
NCT02093741
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00289536
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
NCT02634723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rAHF-PFM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
* Subject has been prescribed ADVATE by their treating physician
* Subject may be of any age
* Subject or parent/legally authorized representative has provided written informed consent
Exclusion Criteria
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baxter BioScience
INDUSTRY
Baxalta now part of Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PHOENIX CHILDRENS Hospital
Phoenix, Arizona, United States
Arkansas Childrens Hospital
Little Rock, Arkansas, United States
City of Hope National Medical Center
Duarte, California, United States
LONG BEACH MEMORIAL MED Center
Long Beach, California, United States
Children´s Hospital Los Angeles, Hemophilia Comprehensive Care Center, Division of Pediatric Hematology/Oncology
Los Angeles, California, United States
Valley Children'S Hospital
Madera, California, United States
Children'S Hospital of S.W. Florida
Fort Myers, Florida, United States
BIODORON
Hollywood, Florida, United States
Nemours Children'S Clinic
Jacksonville, Florida, United States
NEMOURS CHILDREN'S CLINIC- Orlando
Orlando, Florida, United States
Tampa Children'S Hospital At St. Joes
Tampa, Florida, United States
University of Southern Florida
Tampa, Florida, United States
Rush Presbyterian - St. Lukes Medical Center
Chicago, Illinois, United States
Children´s Memorial Hospital
Chicago, Illinois, United States
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics
Iowa City, Iowa, United States
Tulane Univ Hosp & Clinic
New Orleans, Louisiana, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
University of Michigan Med. Ctr Htc
Ann Arbor, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
PHS DEVOS CHILDRENS Hospital
Grand Rapids, Michigan, United States
MUNSON MED Center
Traverse City, Michigan, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
St. Louis Children'S Hospital
St Louis, Missouri, United States
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
Ted R. Montoya Hemophilia Treatment Center
Albuquerque, New Mexico, United States
North Carolina Baptist Hospital, Hematology/Oncology Medical Center Boulevard
Winston-Salem, North Carolina, United States
Phs Childrens Hosp Med Ctr Akron
Akron, Ohio, United States
Children´s Hospital Medical Center Pharmacy, Hemophilia Treatment Center
Cincinnati, Ohio, United States
Youngstown HTC
Youngstown, Ohio, United States
Childrens Hosp of Philadelphia
Philadelphia, Pennsylvania, United States
Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
St. Christopher´s Hospital for Children, Section of Hematology/Oncology
Philadelphia, Pennsylvania, United States
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States
Phs-So Tx Hemo Ctr-San Antonio
San Antonio, Texas, United States
Children'S Hospital of the King'S Daughters
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADVATE PASS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.